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Introduction
The Hippo signaling pathway controls organ size through 
the regulation of cell cycle, proliferation and apoptosis (1,2). 
It was discovered and linked for the first time to human 
cancer in 2002 (3). In this review we will briefly introduce 
this pathway, with an emphasis on components that are 
altered in human cancers, and then we will focus on its 
role in malignant pleural mesothelioma (MPM) and finally 
present potential implication for the therapy of MPM. 
The Hippo/Yes-associated protein (YAP) pathway 
in cancer
The mammalian components of Hippo pathway (Figure 1) 
include Serine/threonine kinase 3 and 4 (STK3 and 4, also 
called MST2 and 1, orthologs of Drosophila Hippo), SAV1, 
and serine/threonine kinase large tumor suppressor 1 and 
2 (LATS1 and 2) (4). Neurofibromin 2 (NF2) (product of 
NF2 gene), also called merlin, a member of the Ezrin ezrin/
radixin/moesin protein family, promotes plasma membrane 
association of LATS which results in phosphorylation and 
activation of LATS1/2 by MST and other not yet known 
kinases (5). Activation of LATS inhibits the transcriptional 
co-activator YAP and the co-activator with PDZ-binding 
motif (TAZ) through their phosphorylation. Indeed, 
phosphorylated YAP/TAZ cannot accumulate into the 
nucleus and this hinders their co-transcriptional activity. 
The dysfunction of Hippo pathway, which leads to 
increased YAP/TAZ activity with an underphosphorylated 
form in the nucleus (6), induces oncogenic transformation 
due to the activation of transcription factors including 
transcription enhancers activation domain (TEAD) family 
members (7). In mammals, there are four TEAD family 
members: TEAD1-4 which have a distinct but not mutually 
exclusive expression pattern (8). TEAD on its own is unable 
to induce gene expression and requires additional factors or 
co-activators for gene expression (8). Upon binding TEADs 
YAP/TAZ up-regulates the expression of several growth 
promoting factors, including secretory proteins connective 
tissue growth factor (CTGF) and Cyr61 (7), AXL receptor 
tyrosine kinase (9), c-myc and survivin (10,11).
Amplification of YAP-containing chromosome 11q22 
amplicon is frequently observed in several human tumors. 
High levels of YAP are observed in human liver tumors 
and YAP is a key driver of hepatocellular carcinoma 
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tumorigenesis (12,13). High YAP levels are also seen in about 
15% of ovarian cancers where it has been correlated with 
poor patient prognosis (14). Similarly, a correlation between 
high YAP expression and poor prognosis has been identified 
in non-small cell lung cancer and esophageal squamous 
cell carcinoma (15,16). YAP overexpression is also seen in 
medulloblastoma (17) intracranial ependymoma (18) and 
oral squamous cell carcinoma (19). Also, YAP plays a role 
in human colorectal cancer progression (20). Mutations 
in Mst1, Mst2, LATS1 and LATS2 are not common but 
epigenetic silencing of these genes has been reported (21-23). 
Hippo pathway activity may also be altered though 
crosstalk with other signalling pathways, which harbour 
oncogenic alteration [reviewed in (24)]. The Hippo 
pathway has been implicated in cell contact inhibition, 
as YAP/TAZ display a dramatic cell density dependent 
subcellular localization and phosphorylation (25). In 
addition, mechanic stress has also been shown to modulate 
YAP/TAZ activity (26). Recent studies have shown that 
YAP activity is regulated by G-protein-coupled receptor 
signaling (27,28). In this context it is of particular interest 
the activation of YAP/TAZ by thrombin and protease-
activated receptor PAR1 (29), since thrombin is generated 
at sites of tissue injury to promote wound healing. In 
addition inhibition of mevalonate pathway with simvastatin 
decreases nuclear YAP (30).
The interaction with sonic hedgehog stem signalling 
pathway in mesothelioma will be detailed below. 
The Hippo/YAP pathway in MPM
MPM is an aggressive human malignancy (31). MPM is mostly 
associated with asbestos exposure and the latency period 
after initial exposure is typically longer than 30 years (32). 
MPM is a rare disease with a 15-year cumulative frequency 
during 1994-2008 in the 56 countries reporting MPM to be 
174,300 (33); however the real incidence of MPM is unknown, 
since there are countries in which MPM mortality is not 
reported, including asbestos-producing countries such as 
Russia, Kazakhstan, China and India (33). MPM mortality 
rates are estimated to increase by 5-10% per year in most 
industrialized countries until about 2020 (34). Despite 
treatment with chemotherapy, radiation therapy or surgery, 
the disease carries a poor prognosis. The median survival time 
Figure 1 In normal tissue repair NF2 activates the Hippo pathway, an essential regulator of cell proliferation. Key components of the 
Hippo pathway include two kinases: Mst and Lats. The sequential activation of these kinases leads to phosphorylation of the transcription 
factor YAP. When Hippo signaling is attenuated, e.g., in NF2-deficient cancer cells, YAP phosphorylation is reduced, resulting in its nuclear 
localization and regulation of target genes such as CTGF, Cyr61, AXL and survivin. Survivin is also controlled by nuclear NF2.
NF2 is a “gatekeeper” during tissue repair
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stimulation of repair in NF2 signaling 
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of patients after diagnosis is only 7-12 months (35). 
The mechanism of development of MPM after exposure 
to asbestos fibres is not well understood. Few hypotheses 
can be proposed based on experimental data and observation 
of clinical samples, some of which has been detailed in 
several reviews (36-42). Chronic tissue repair activates stem 
cell signalling pathways to regenerate the tissue but, because 
of persistent system stimulation, oncogenic events occur 
leading to the formation of a tumor (43). Cells that are 
stimulated to proliferate upon asbestos fibres exposure may 
be undifferentiated precursor cells, as it has been shown for 
mesothelial regeneration after injury (44). Undifferentiated 
precursor cells have been recently described in normal 
mesothelial primary cultures (45). The activation of stem 
cell signalling would normally be kept under control, but, 
because of persistent system stimulation, oncogenic events 
occur leading to the formation of a tumor (43). In line with 
such hypothesis one would expect the oncogenic events to 
occur within the components responsible for homeostasis in 
tissue repair and in control of stem cell signalling. Activated 
stem cell signalling has already been suggested in MPM 
by the presence of an 11-gene signature, correlated with a 
stem-cell-like expression profile, which is associated with 
a poor prognosis in patients with MPM (46). Knowledge 
about common alterations observed in MPM, which are 
detailed below, confirms that alteration in NF2 signalling, 
which is responsible for homeostasis in tissue repair and in 
the control of stem cell signalling, is the ideal target for an 
oncogenic event to occur during the development of MPM. 
This hypothesis is supported by the observation that Hippo 
pathway restricts the oncogenic potential of intestinal 
regeneration program induced after injury by dextran 
sodium sulfate (47).
Data mining of version 68 of the catalogue of somatic 
mutations in cancer (COSMIC, http://www.sanger.ac.uk/
cosmic) (48) reveals that the genes that are mostly mutated 
in MPM (Figure 2) are cyclin-dependent kinase activator 
inhibitor (CDKN2A), neurofibromatosis type 2 (NF2) and 
BRCA-associated protein 1 (BAP1). Although the total number 
of samples (<500, status February 2014) screened is too low 
to confidently predict mutation frequencies this estimate 
is nevertheless useful to infer a general MPM profile. 
CDKN2A and NF2 are the two most abundantly mutated 
genes in MPM. Indeed, MPM lack expression of both 
CDKN2A encoded proteins p16 and ARF (49,50) due to 
gene deletion (51-53) or methylation (54-56). Mutations in 
NF2 gene have been found in about 40% of mesothelioma 
(57-59). In MPM tumors with no detectable genetic 
Figure 2 Data mining of version 67 of the catalogue of somatic mutations in cancer (COSMIC, http://www.sanger.ac.uk/cosmic), 
reveals that the genes that are mostly mutated in malignant pleural mesothelioma are cyclin-dependent kinase activator inhibitor (CDKN2A), 
neurofibromatosis type 2 (NF2) and BRCA-associated protein 1 (BAP1).
Genes most abundantly mutated in Malignant Pleural 
Mesothelioma (COSMIC database)
Top 20 genes
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CDKN2A (55%)
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BAP1 (32%)
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TP53 (6%)
KRAS (4%)
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alterations of NF2, its activity is downregulated. Indeed, the 
activity of NF2 is controlled by phosphorylation (Figure 3), 
which depending on the phosphorylated amino acid, leads 
to functional inactivation (60,61) or AKT-dependent 
degradation (62). Experimental animal models indicate that 
disruption of the NF2 signalling pathway, together with 
a deficiency in CDKN2A, is essential for mesothelioma 
development (63-65). NF2 is an upstream regulator of the 
Hippo signaling cascade, which is conserved from Drosophila 
to mammalians (10). The NF2/Hippo connection is 
supported by mouse genetics, wherein heterozygosity of Yap 
greatly suppresses the Nf2-deficient phenotype (66). 
It has been proposed that genes which are inactivated 
in a given tumor type and directly regulate tumor growth 
by either inhibiting growth or promoting death are 
“gatekeeper” genes (67). According to the data mentioned 
above, NF2 does correspond to this definition and should 
be considered a “gatekeeper” in mesothelioma. Indeed, 
NF2 mediates contact-dependent inhibition of proliferation 
by both sensing cell-cell contact and intercepting mitogenic 
signalling initiated at the plasma membrane (68). In cultured 
mammalian cells, NF2 inhibits internalization, effector 
complexing and downstream signalling of activated EGFR 
upon cell-cell contact. This is consistent with the idea that 
NF2/merlin normally sequesters EGFR into non-signalling 
plasma membrane compartments (69). In addition, NF2 
is required for the assembly, but not the maintenance, of 
apico-lateral junctional complexes (70) which means that 
NF2 loss will be most important when it occurs in dividing 
cells, for example during tissue repair. Cells that cannot 
form apico-lateral junctional complexes will be unable 
to form a well-organized tissue and will be resistant to 
contact-dependent growth arrest. A role of NF2 in tissue 
repair is further supported by the observation that the 
active form of NF2 suppresses tumorigenesis by migrating 
into the nucleus where it inhibits the E3 ubiquitin ligase 
CRL4 and through that controls a subset of Hippo pathway 
target genes (71). This recent observation is consistent with 
previous evidence of NF2 signaling-dependent activation of 
the Hippo pathway (72). 
Data from the group of Sekido (73) and the group of 
Ladanyi (74) indicate that NF2/Hippo signalling is disrupted 
in most MPM. It is important to note that downstream of 
such a disrupted signalling, TEAD1/YAP1 are activated 
and YAP/TEAD1 are necessary, but not sufficient (75), for 
the overexpression of mesothelin. Mesothelin is expressed 
in normal mesothelium (76) and is a marker of epithelioid 
mesothelioma (77). 
YAP is constitutively active in more than 70% of primary 
MPM (73), it has been originally described in an inducible 
transgenic model to be involved in organ size control 
paralleled by a 30-fold increase in survivin expression (10). A 
Regulation of NF2 by phosphorylation
(Protein kinase 
C-potentiated 
phosphatase 
onhibitor of 17 kDa)
Figure 3 The function of tumor suppressor NF2 is inactivated by genetic alterations or it is controlled by phosphorylation, which depending 
on the phosphorylated amino acid, leads to functional inactivation or AKT-dependent degradation. NF2 phosphorylation on Ser518 is 
favored when levels of protein kinase C-potentiated phosphatase inhibitor of 17 KDa (CPI-17), which inhibits the phosphatase reactivating 
NF2, are high. On the other hand PTEN deletion results in increased AKT activity and NF2 degradation.
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recent study has showed that it controls survivin expression 
in MPM (78). We have observed that Hedgehog signaling 
is activated in MPM, consistent with the re-activation 
of a signalling known to be essential during embryonic 
mesothelium development (79). Treatment with an 
inhibitor of Hedgehog pathway (HhAntag) of mesothelioma 
cells, grown in cell culture conditions favoring stemness, 
was arresting cells growth and this was accompanied by 
decreased levels of survivin (80). Survivin is not described 
as a direct target downstream Hedgehog pathway. Hence, 
we sought for other transcription activators known to be 
expressed in MPM and to regulate survivin expression 
and the most obvious was YAP. We confirmed nuclear 
expression of YAP in MPM and observed that HhAntag 
reduced YAP protein levels. Transient transfection of a 
constitutively active YAP (81) rescued HhAntag-dependent 
survivin decrease, confirming the interaction between 
Hedgehog and YAP signaling. Tumor bearing mice were 
randomized in two groups receiving either solvent or 
HhAntag. The in vivo HhAntag treatment dosage (38 mg/kg 
bw, administered twice daily by oral gavage, 5 d/week) 
was chosen based on therapeutic range reported in the 
literature (82). HhAntag led to a significant 35% decrease 
of the tumor volume after the two weeks of treatment. 
At the end of dosing regimen, animals were euthanized 
in order to collect tumor tissue for RNA extraction and 
immunohistochemical analysis. A different expression 
profile indicating changes in both tumor and stromal tissue 
were obtained in the two groups. The effect of HhAntag on 
tumor volumes was also accompanied by a significant 43% 
decrease in Ki-67 labelling index. Furthermore, consistent 
with in vitro experiments, we observed a significant 32% 
decrease in nuclear YAP immunostaining in HhAntag 
treated tumors. The observation that HhAntag decreases 
YAP protein is consistent with the role of Hedgehog 
signaling in maintaining YAP protein stability (17).
More recently, the modulation of YAP by the AJUBA 
family has been investigated in MPM (83). The mammalian 
Ajuba family comprises three proteins AJUBA, LIMD1, and 
WTIP characterized by a so-called, LIM domain. The LIM 
domain defines a cysteine-rich double zinc finger initially 
identified in three developmentally important transcription 
factors, Caenorhabditis elegans Lin-11, rat Isl-1, and C. 
elegans mec-3, from which the acronym LIM is derived (84). 
Although in Drosophila the unique AJUBA family member 
ortholog activates YAP by binding LATS (85), in MPM the 
three different LIM family members seem not to have all 
the same YAP-activating properties (83).
Implications for therapy
Under the hypothesis that disruption of NF2 function acts 
as “driver” in MPM, therapeutic intervention on genes that 
are normally kept under control by NF2 and the Hippo 
pathway such as, e.g., survivin, would be a reasonable 
approach. However, this might not be easy to implement. 
In the context of MPM harboring mutated NF2/Hippo 
pathway, cancer cells may be addicted to the activity of YAP. 
Liu-Chittenden et al. (86) screened a Johns Hopkins Drug 
Library, a collection of >3,300 drugs, for compounds that 
could inhibit the transcriptional activity of YAP in vitro. 
Three compounds related to porphyrin were identified with 
this assay. One of these, verteporfin, is in clinical use as a 
photosensitizer in photocoagulation therapy for macular 
degeneration. Verteporfin was moderately effective at 
blocking mouse Yap1-overexpression- or loss of Nf2-driven 
hepatic tumorigenesis. These data suggest the application 
of these compounds as anticancer therapies independently 
of their photosensitizing roles. 
Downstream G-coupled receptor signall ing we 
mentioned above YAP activation via thrombin/PAR1 (29) 
and this activation could be relevant in MPM that depend 
on PAR1 for growth (87). In these cases one potential 
option for therapy might be PAR-1 antagonists pepducins 
such as P1pal-12 (88) which is a cell-penetrating peptide 
derived from the third intracellular loop of PAR-1. Once 
inserted into the plasma membrane it is delivered to the 
PAR-1 intracellular surface, thereby interfering with the 
receptor/G-protein interaction. Lysophosphatidic acid 
(LPA) stimulates YAP activity (27) and has also been 
described to stimulate MPM growth (89), offering another 
opportunity for intervention.
Simvastatin decreases nuclear YAP and induces growth 
arrest by interfering with protein geranylgeranylation (30). 
The same mechanism may participate to lovastatin-
mediated protective effect against cisplatin in proliferating 
normal mesothelial cells (90).
Other druggable targets, which might be relevant in 
other cancer types, have been summarized in two recent 
reviews (91,92).
In MPM the strategy may depend on upstream signalling: 
activated stem signalling, thrombin/PAR1 and LPA/LPA 
receptor are all potentially interesting targets to inhibit in 
view of interfering with YAP activation. Nevertheless, for 
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the time being, only for Hedgehog stem signalling a direct 
link with YAP activation has been demonstrated (80).
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